---
figid: PMC9503112__ijms-23-10854-g003
pmcid: PMC9503112
image_filename: ijms-23-10854-g003.jpg
figure_link: /pmc/articles/PMC9503112/figure/ijms-23-10854-f003/
number: Figure 3
figure_title: ''
caption: Characteristics of cytotoxicity. (a) Average IC50 for the compounds 7a–7k.
  The most active compounds are shown in blue. (b) Synergistic effect of 1 mM metformin
  (MF) and 4 nM compound 7c on the growth of MCF7 cells. (c) Effect of 300 µM MF on
  MCF7 proliferation. (d) IC50 for 7c and 7c + MF 300 µM for Eahy926, Colon26, and
  MCF7.
article_title: Synthesis, Molecular Docking, In Vitro and In Vivo Studies of Novel
  Dimorpholinoquinazoline-Based Potential Inhibitors of PI3K/Akt/mTOR Pathway.
citation: Maria V. Zapevalova, et al. Int J Mol Sci. 2022 Sep;23(18):10854.
year: '2022'

doi: 10.3390/ijms231810854
journal_title: International Journal of Molecular Sciences
journal_nlm_ta: Int J Mol Sci
publisher_name: MDPI

keywords:
- dimorpholinoquinazoline
- cancer
- PI3K/Akt/mTOR inhibitor
- S6K
- kinase inhibition activity

---
